VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide

British Journal of Cancer

Volumn 109, Issue 4, 2013, Pages 957-964

  Orlandi, P ^a,b   Fontana, A ^b,c   Fioravanti, A ^a,b   Di Desidero, T ^a,b   Galli, L ^b,c   Derosa, L ^b,c   Canu, B ^a,b   Marconcini, R ^b,c   Biasco, E ^b,c   Solini, A ^a   Francia, G ^d   Danesi, R ^a   Falcone, A ^b,c   Bocci, G ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d UNIVERSITY OF TEXAS AT EL PASO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GENOMIC DNA; PROSTATE SPECIFIC ANTIGEN; VASCULOTROPIN A;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DIARRHEA; GENOTYPE; HUMAN; MALE; METRONOMIC DRUG ADMINISTRATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADMINISTRATION, METRONOMIC; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; CYCLOOXYGENASE 2 INHIBITORS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84883145648     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.398     Document Type: Article

References (44)

1. Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F, Di Paolo A, Masi G, Fontana A, Lucchesi S, Arrighi G, Giusiani M, Ciarlo A, Brandi G, Danesi R, Kerbel RS, Falcone A, Bocci G (2012) Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis 15(2): 275-286.
2. Bocci G, Loupakis F (2011) Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle. Pharmacogenomics 12(8): 1077-1080.
3. Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, Del Tacca M (2005) Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 16(8): 1243-1252.
4. Botelho F, Pina F, Lunet N (2010) VEGF and prostatic cancer: a systematic review. Eur J Cancer Prev 19(5): 385-392.
5. Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, Rabascio C, Dellapasqua S, Campagnoli E, Shaked Y, Goldhirsch A, Colleoni M, Bertolini F (2009) Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 15(24): 7652-7657.
6. Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, Kerbel RS (2011) Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 13(1): 40-48.
7. Emmenegger U, Francia G, Shaked Y, Kerbel RS (2010) Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer. Recent Results Cancer Res 180: 165-183.
8. Emmenegger U, Shaked Y, Man S, Bocci G, Spasojevic I, Francia G, Kouri A, Coke R, Cruz-Munoz W, Ludeman SM, Colvin OM, Kerbel RS (2007) Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. Mol Cancer Ther 6(8): 2280-2289.
9. Etienne-Grimaldi MC, Formento P, Degeorges A, Pierga JY, Delva R, Pivot X, Dalenc F, Espie M, Veyret C, Formento JL, Francoual M, Piutti M, de Cremoux P, Milano G (2011) Prospective analysis of the impact of VEGFA gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol 71(6): 921-928.
10. Excoffier L, Laval G, Schneider S (2005) Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online 1: 47-50.
11. Fontana A, Bocci G, Galli L, D'Arcangelo M, Derosa L, Fioravanti A, Orlandi P, Barletta MT, Landi L, Bursi S, Minuti G, Bona E, Grazzini I, Danesi R, Falcone A (2010a) Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer. J Am Geriatr Soc 58(5): 986-988.
12. Fontana A, Falcone A, Derosa L, Di Desidero T, Danesi R, Bocci G (2010b) Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients? Drugs Aging 27(9): 689-696.
13. Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, Bursi S, Allegrini G, Fontana E, Di Marsico R, Antonuzzo A, D'Arcangelo M, Danesi R, Del Tacca M, Falcone A, Bocci G (2009) Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 15(15): 4954-4962.
14. Hrouda D, Nicol DL, Gardiner RA (2003) The role of angiogenesis in prostate development and the pathogenesis of prostate cancer. Urol Res 30(6): 347-355.
15. Hsiao PJ, Lu MY, Chiang FY, Shin SJ, Tai YD, Juo SH (2007) Vascular endothelial growth factor gene polymorphisms in thyroid cancer. J Endocrinol 195(2): 265-270.
16. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J, Figg WD (2009) The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 8(9): 2496-2508.
17. Jelkmann W (2001) Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47(4): 617-623.
18. Kerbel RS, Kamen BA (2004) The anti-Angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6): 423-436.
19. Kluetz PG, Figg WD, Dahut WL (2010) Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother 11(2): 233-247.
20. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46(3): 293-298.
21. Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Di Desidero T, Canu B, Schirripa M, Frumento P, Di Paolo A, Danesi R, Falcone A, Bocci G (2011) Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 104(8): 1262-1269.
22. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS (2002) Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62(10): 2731-2735.
23. Nelius T, Klatte T, de Riese W, Haynes A, Filleur S (2010) Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol 27(2): 363-367.
24. Nelius T, Rinard K, Filleur S (2011) Oral/metronomic cyclophosphamidebased chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature. Cancer Treat Rev 37(6): 444-455.
25. Nicholson B, Theodorescu D (2004) Angiogenesis and prostate cancer tumor growth. J Cell Biochem 91(1): 125-150.
26. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6): 649-655.
27. Pander J, Gelderblom H, Guchelaar HJ (2007) Pharmacogenetics of EGFR and VEGF inhibition. Drug Discov Today 12(23-24): 1054-1060.
28. Pasqualetti G, Danesi R, Del Tacca M, Bocci G (2007) Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-Angiogenic therapy. Pharmacogenomics 8(1): 49-66.
29. Pasquier E, Kavallaris M, Andre N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7(8): 455-465.
30. Penel N, Adenis A, Bocci G (2012) Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol 82(1): 40-50.
31. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS (1995) Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 14(4): 263-277.
32. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37(6): 443-448.
33. Rozados VR, Mainetti LE, Rico MJ, Zacarias Fluck MF, Matar P, Scharovsky OG (2010) The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide. Oncol Res 18(11-12): 601-605.
34. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7): 1148-1159.
35. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28): 4672-4678.
36. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, Morgan R, Gandara D, Scudder S, Oza A, Hirte H, Fleming G, Roman L, Lenz HJ (2008) Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 14(22): 7554-7563.
37. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV, Harden PN (2002) Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13(1): 260-264.
38. Stephens M, Scheet P (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 76(3): 449-462.
39. Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68(4): 978-989.
40. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, Riddick AC (2010) The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int 105(1): 8-13.
41. Taioli E, Flores-Obando RE, Agalliu I, Blanchet P, Bunker CH, Ferrell RE, Jackson M, Kidd LC, Kolb S, Lavender NA, McFarlane-Anderson N, Morrison SS, Multigner L, Ostrande EA, Park JY, Patrick AL, Rebbeck TR, Romana M, Stanford JL, Ukoli F, Vancleave TT, Zeigler-Johnson CM, Mutetwa B, Ragin C (2011) Multi-institutional prostate cancer study of genetic susceptibility in populations of African descent. Carcinogenesis 32(9): 1361-1365.
42. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS (2002) A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 99(7): 4349-4354.
43. Vaziri SA, Kim J, Ganapathi MK, Ganapathi R (2010) Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. Curr Oncol Rep 12(2): 102-108.
44. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12(8): 1232-1235.